Endosomolytic Anionic Polymer for the Cytoplasmic Delivery of siRNAs in Localized In Vivo Applications. (13th September 2012)

• Record Type: Journal Article
• Authors: Khormaee, Sariah; Choi, Yong; Shen, Michael J.; Xu, Biying; Wu, Haitao; Griffiths, Gary L.; Chen, Rongjun; Slater, Nigel K. H.; Park, John K.
• Is Part Of: Advanced functional materials. Volume 23:Number 5(2013)
• Page Start: 565
• Page End: 574
• Publication Date: 2012-09-13
• Subjects: Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adfm.201201945
• Languages: English
• ISSNs: 1616-301X

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>The use of small interfering RNAs (siRNAs) to down‐regulate the expression of disease‐associated proteins carries significant promise for the treatment of a variety of clinical disorders. One of the main barriers to the widespread clinical use of siRNAs, however, is their entrapment and degradation within the endolysosomal pathway of target cells. Here, the trafficking and function of PP75, a nontoxic, biodegradable, lipid membrane disruptive anionic polymer composed of phenylalanine derivatized poly(L‐lysine isophthalamide) is reported. PP75 is readily endocytosed by cells, safely permeabilizes endolysosomes in a pH dependent manner and facilitates the transfer of co‐endocytosed materials directly into the cytoplasm. The covalent attachment of siRNAs to PP75 using disulfide linkages generates conjugates that effectively traffic siRNAs to the cytoplasm of target cells both in vitro and in vivo. In a subcutaneous malignant glioma tumor model, a locally delivered PP75‐stathmin siRNA conjugate decreases stathmin expression in tumor cells and, in combination with the nitrosourea chemotherapy carmustine, is highly effective at inhibiting tumor growth. PP75 may be clinically useful for the local delivery of siRNAs, in particular for the treatment of solid tumors.</p> </abstract>